Please login to order a test.
Evaluate toxicity; monitor therapeutic levels
Therapeutic: 40−100 μg/mL
Ethosuximide is well absorbed orally, and the peak plasma concentration occurs in one to four hours. It is minimally bound to plasma protein and eliminated primarily via hepatic metabolism with 10% to 20% of the administered dose excreted unchanged in the urine. The half-life is variable but averages 52 to 56 hours in adults and 32 to 41 hours in children. Breast milk concentrations are slightly less than corresponding plasma concentrations, but problems related to breast-feeding in humans have not been documented. Control of absence seizures usually is achieved with plasma concentrations of 40−100 μg/mL, but concentrations up to 160 μg/mL may be required and are tolerated in some patients. As is the case with other antiepileptic drugs metabolized by the P450 enzyme system, co-administration of carbamazepine, phenytoin, phenobarbital, or primidone will result in decreased ethosuximide levels, whereas valproic acid can increase ethosuximide levels.1
Serum or plasma
Transfer separated serum or plasma to a plastic transport tube. Oral: peak: two to four hours after dose; trough: immediately prior to next dose. Peak or trough levels may be used to monitor therapy because blood levels are fairly constant.
Causes for Rejection
Gel-barrier tube; hemolysis; lipemia; gross bacterial contamination
State other drugs taken by patient.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|007443||Ethosuximide (Zarontin), Serum||3616-0||007443||Ethosuximide (Zarontin), Serum||ug/mL||3616-0|